SUPERCOX WATER SOLUBLE POWDER (Each kg contains Sulfamethazine/ Sodium sulfaquinoxaline/ Trimethorprim/ Oxytetracycline hydrochloride/ Vitamin A/ Vitamin K 200g/ 25g/ 65g/ 200g/ 5,000,000iu/ 5g

Indications

• Bacterial infections (e.g. Chlamydia, Rickettsia, Mycoplasma)
• Acne
• Prophylaxis of asymptomatic meningococcal carrier state (not recommended)

Dosage

Adults: For adult patients, the typical dosage of oxytetracycline for susceptible infections is 100 mg twice daily for 5 days. For other conditions, such as acne, the dosage may be 500 mg twice daily, usually for a duration of 6 to 12 weeks, with the possibility of repeating the course intermittently.

Mechanism of action

Oxytetracycline exerts its antibacterial effects by binding to the 30S ribosomal subunit of bacteria, inhibiting the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This action prevents the synthesis of proteins essential for bacterial growth and replication, leading to the bacteriostatic effect of the drug.

Pharmacodynamics

The pharmacodynamics of oxytetracycline involve its ability to inhibit bacterial protein synthesis, which is critical for the growth and reproduction of bacteria. The drug demonstrates a broad spectrum of activity against both Gram-positive and Gram-negative organisms, as well as some atypical pathogens. Its effectiveness can be influenced by the presence of tetracycline resistance mechanisms in certain bacterial strains.

Pharmacokinetics

Oxytetracycline is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring approximately 1-2 hours after oral administration. It has a relatively long half-life of about 8-10 hours, allowing for twice-daily dosing. The drug is widely distributed in body tissues and fluids, including the liver, kidneys, and lungs, but is less effective in central nervous system infections due to limited penetration. It is primarily excreted via urine, and dosage adjustments may be necessary in patients with renal impairment.

Contra-indications

• Children under 12 years due to deposition in growing bone and teeth, causing staining and occasionally dental hypoplasia

Adverse effects

• Gastrointestinal disturbances
• Photosensitivity
• Dental discoloration
• Hepatotoxicity
• Renal impairment
• Skin reactions including rash and urticaria
• Ataxia
• Hearing impairment
• Colitis
• Systemic lupus erythematosus exacerbation

Interactions

• Antacids and supplements containing calcium, magnesium, or iron may reduce absorption
• Oral contraceptives may be less effective
• Other tetracyclines
• Warfarin (may increase anticoagulant effect)

Precautions

• Use with caution in patients with renal impairment
• Monitor for hepatic toxicity in long-term use
• Patients should be advised to avoid excessive sunlight exposure
• Discontinue if systemic lupus erythematosus develops or worsens

Pregnancy

Oxytetracycline is contraindicated during pregnancy due to potential harm to fetal development, particularly affecting bone and dental health.

Breast-feeding

Use with caution; oxytetracycline is excreted in breast milk and may affect the infant's dental health.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oxytetracycline 250 mg tablets
• Oxytetracycline oral suspension
• Oxytetracycline oral solution

Indications

• Vitamin K deficiency
• Coagulation disorders due to vitamin K deficiency
• Reversal of anticoagulation in patients on warfarin therapy
• Neonatal prophylaxis of vitamin K deficiency bleeding

Dosage

Adults: For adults, the typical dosage is 1-5 mg administered orally or via slow intravenous injection. Dosing may be adjusted based on clinical response and INR levels.

Mechanism of action

Vitamin K acts as a cofactor for the enzyme gamma-carboxylase, which catalyzes the carboxylation of specific glutamic acid residues on clotting factors II (prothrombin), VII, IX, and X. This carboxylation allows these factors to bind calcium ions, which is essential for their activation and subsequent role in the coagulation cascade. Additionally, vitamin K is involved in carboxylating matrix proteins in chondrocytes, possibly influencing bone density and vascular calcification.

Pharmacodynamics

Phytomenadione is indicated in the management of coagulation disorders resulting from vitamin K deficiency. It promotes the hepatic biosynthesis of prothrombin and other clotting factors, restoring normal clotting function. Its long duration of action and wide therapeutic index make it a safe option for patients requiring vitamin K supplementation, but monitoring of prothrombin time is essential during therapy. Hypersensitivity reactions may occur, especially with parenteral administration.

Pharmacokinetics

Phytomenadione is absorbed in the intestine and transported in the lymphatic system. It is then stored in the liver and released into circulation as needed for clotting factor synthesis. Vitamin K has a long half-life, allowing for sustained action, and is cycled in the body, contributing to its prolonged effects. The elimination occurs primarily through the hepatic pathway, and caution is advised in patients with hepatic impairment.

Contra-indications

• Hypersensitivity to phytomenadione or any of its excipients
• Severe hepatic impairment
• Hyperbilirubinaemia in neonates
• Known risk of hemolytic anemia in newborns

Adverse effects

• Anaphylactoid reactions (especially with intravenous use)
• Hypersensitivity reactions
• Flushing
• Rash
• Gastrointestinal disturbances

Interactions

• Anticoagulants (e.g., warfarin) - may require dose adjustment
• Cholestyramine - may reduce absorption of vitamin K
• Mineral oil - may interfere with absorption
• Antibiotics (e.g., cephalosporins) - may affect vitamin K synthesis by gut flora

Precautions

• Use with caution in patients with G6PD deficiency due to risk of hemolysis
• Monitor INR closely in patients with hepatic impairment
• Use intravenous preparations slowly to avoid vascular collapse
• Caution in elderly patients due to altered pharmacokinetics

Pregnancy

Use only if potential benefit outweighs risk, especially in late pregnancy due to risk of neonatal hemolytic anemia.

Breast-feeding

Present in breast milk; caution is advised if large doses are administered.

Storage

Store at room temperature, away from light and moisture. Protect from freezing.

Formulations

• Capsules (200 units, 400 units)
• Oral solutions
• Tablets (10 mg)
• Injectable solution for intravenous use

Indications

• Vitamin A deficiency
• Night blindness
• Impaired wound healing
• Epithelial disorders

Dosage

Children: Refer to BNF for Children for specific paediatric dosing information.

Adults: Refer to BNF for specific adult dosing information.

Mechanism of action

Retinol is converted in the retina to 11-cis-retinal, which is crucial for the conversion of light into neural signals necessary for vision. It binds to opsin in rhodopsin, facilitating the isomerization to all-trans-retinal upon exposure to light, thus triggering visual signaling. Additionally, retinol interacts with retinoic acid receptors (RARs) and retinoid-X receptors (RXRs) as transcription factors, modulating gene expression related to cellular differentiation and growth.

Pharmacodynamics

Vitamin A is effective in treating Vitamin A deficiency, which can lead to vision impairment and other health issues. It plays a critical role in various biological processes including vision, cellular differentiation, reproduction, and immune system function. Its deficiency can cause symptoms such as night blindness and impaired wound healing, while adequate levels support growth and development.

Pharmacokinetics

Retinol is absorbed from the gastrointestinal tract and stored in the liver, where it can be mobilized as needed. It undergoes metabolism primarily in the liver, where it is converted to retinal and retinoic acid, the active forms of Vitamin A. The elimination half-life varies, but retinol is generally excreted in urine and bile. The bioavailability can be affected by dietary fat intake.

Adverse effects

• Nausea
• Vomiting
• Headache
• Dizziness
• Fatigue
• Irritability
• Dry skin
• Peeling of skin
• Itching
• Blurred vision

Precautions

• Use with caution in patients with liver disease due to potential hepatotoxicity.
• Monitor for signs of vitamin A toxicity, especially in patients on high doses or prolonged therapy.
• Caution in patients with a history of alcohol abuse, as it may exacerbate liver conditions.

Pregnancy

Retinol should be used with caution during pregnancy due to the risk of teratogenic effects. High doses of vitamin A can lead to fetal malformations.

Breast-feeding

Retinol is generally considered safe during breastfeeding, but excessive intake should be avoided to prevent potential adverse effects on the infant.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

• Capsules
• Tablets
• Oral solutions
• Topical preparations

Indications

• Urinary tract infections
• Respiratory tract infections
• Skin infections
• Bacterial meningitis
• Toxoplasmosis

Dosage

Children: For children, the dosage is based on body weight. The usual dose is 100 to 200 mg/kg/day in divided doses, not exceeding 1 g per day.

Adults: The usual adult dose is 1 to 2 g initially, followed by 0.5 to 1 g every 12 hours as needed, depending on the severity of the infection.

Mechanism of action

Sulfamethazine inhibits the enzymatic conversion of pteridine and p-aminobenzoic acid (PABA) to dihydropteroic acid by competing with PABA for binding to dihydrofolate synthetase. This enzyme is essential for the synthesis of tetrahydrofolic acid (THF), which is required for the synthesis of purines and deoxythymidine monophosphate (dTMP). By inhibiting THF synthesis, sulfamethazine disrupts bacterial growth.

Pharmacodynamics

As a sulfonamide, sulfamethazine acts by inhibiting bacterial synthesis of dihydrofolic acid. It competes with PABA for binding to dihydropteroate synthetase, leading to reduced synthesis of nucleotides and DNA. This bacteriostatic action effectively slows down the growth of susceptible bacteria.

Pharmacokinetics

Sulfamethazine is well absorbed from the gastrointestinal tract, with peak plasma concentrations typically reached within 1 to 4 hours after oral administration. It is metabolized in the liver to various inactive metabolites, and its elimination half-life varies depending on individual metabolism and renal function. The drug is primarily excreted in urine, both as unchanged drug and metabolites.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Rash
• Hematologic reactions (e.g., agranulocytosis, aplastic anemia)
• Allergic reactions
• Photosensitivity
• Liver toxicity

Interactions

• May enhance the effects of anticoagulants (e.g., warfarin)
• May interact with methotrexate, increasing toxicity
• May decrease the effectiveness of oral contraceptives
• Potential interaction with other sulfonamides or drugs that affect renal function

Precautions

• Use with caution in patients with renal impairment
• Caution in patients with a history of sulfonamide allergy
• Monitor for signs of hypersensitivity reactions
• Use cautiously during treatment of infections in pregnant women

Pregnancy

Sulfamethazine should be avoided during pregnancy, particularly in the first trimester, due to the risk of teratogenic effects and potential for hyperbilirubinemia in neonates.

Breast-feeding

Sulfamethazine is excreted in breast milk; caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

• Tablets
• Oral suspension

Indications

• Bacterial infections in veterinary medicine
• Coccidiosis in poultry
• Treatment of certain protozoal infections

Dosage

Children: Refer to the relevant prescribing information for specific dosing guidelines as per clinical condition.

Adults: Refer to the relevant prescribing information for specific dosing guidelines as per clinical condition.

Mechanism of action

Sulfaquinoxaline acts as a competitive antagonist of para-aminobenzoic acid (PABA), a key substrate in the bacterial synthesis of folic acid. By inhibiting the enzyme dihydropteroate synthase, sulfaquinoxaline prevents the incorporation of PABA into dihydropteroic acid, which is the precursor of folic acid. This inhibition disrupts the formation of folic acid necessary for DNA synthesis, thus hindering bacterial cell multiplication. Mammalian cells, which utilize preformed folic acid, are not affected by this mechanism.

Pharmacodynamics

The pharmacodynamics of sulfaquinoxaline are characterized by its ability to inhibit bacterial growth through the blockade of folic acid synthesis. It demonstrates a bacteriostatic effect, meaning it stops bacteria from multiplying rather than killing them directly. The efficacy of sulfaquinoxaline depends on the susceptibility of the bacteria involved and is influenced by the presence of PABA in the environment, which can compete with the drug.

Pharmacokinetics

Sulfaquinoxaline is well absorbed from the gastrointestinal tract and achieves therapeutic levels in the serum. It has a distribution that allows it to penetrate tissues and body fluids. The drug is metabolized in the liver and excreted primarily through the kidneys. The pharmacokinetic profile can be influenced by factors such as the presence of other substances that may compete for absorption or metabolism.

Contra-indications

• Hypersensitivity to sulfonamides
• Severe hepatic or renal impairment
• Porphyria

Adverse effects

• Allergic reactions including rash, itching, and fever
• Gastrointestinal disturbances such as nausea and vomiting
• Hematological effects including leukopenia, thrombocytopenia, and aplastic anemia
• Kernicterus in newborns
• Crystalluria

Interactions

• May enhance the effects of anticoagulants such as warfarin
• Potentially decreases the effectiveness of oral contraceptives
• Can increase the toxicity of methotrexate
• May interact with other drugs that affect renal function

Precautions

• Use with caution in patients with renal impairment
• Monitor for signs of blood dyscrasias
• Adequate hydration is important to prevent crystalluria
• Caution in patients with a history of asthma or allergic reactions

Pregnancy

Use during pregnancy only if clearly needed, as sulfonamides can cross the placenta and may cause harm to the fetus.

Breast-feeding

Breastfeeding is not recommended while taking sulfaquinoxaline due to potential adverse effects on the infant.

Storage

Store at room temperature, away from moisture and heat.

Formulations

• Tablets
• Suspensions
• Injectable forms

Indications

• Urinary tract infections
• Acute exacerbations of chronic bronchitis
• Pneumocystis pneumonia
• Traveler's diarrhea
• Bacterial infections caused by susceptible organisms

Dosage

Children: Refer to BNF for Children for specific doses.

Adults: Refer to local prescribing guidelines for specific doses.

Mechanism of action

Trimethoprim works by selectively inhibiting the enzyme dihydrofolate reductase in bacteria, which is crucial for the conversion of dihydrofolate to tetrahydrofolate. This inhibition results in a decrease in folate synthesis, thereby impeding the production of nucleic acids and proteins essential for bacterial growth and replication.

Pharmacodynamics

Trimethoprim exhibits bactericidal activity against a variety of Gram-positive and Gram-negative bacteria. Its effectiveness is attributed to the disruption of folate metabolism, which is vital for the synthesis of nucleic acids. The drug has a higher affinity for bacterial dihydrofolate reductase than for the human enzyme, leading to the selective toxicity.

Pharmacokinetics

Trimethoprim is well absorbed after oral administration, with peak plasma concentrations typically occurring within 1 to 4 hours. It has a bioavailability of approximately 90%. The drug is widely distributed throughout the body, including into the lungs, kidneys, and prostate. Trimethoprim is primarily eliminated via renal excretion, with about 50-70% of the dose excreted unchanged in the urine. Its half-life is approximately 8 to 10 hours in adults, which may be prolonged in patients with renal impairment.

Contra-indications

• Hypersensitivity to trimethoprim or any of its components
• Severe renal impairment
• Pregnancy (especially during the first trimester)

Adverse effects

• Nausea
• Vomiting
• Rash
• Itching
• Hyperkalemia
• Hematological reactions (e.g., leukopenia, thrombocytopenia)
• Elevated liver enzymes

Interactions

• Other medications that may increase serum potassium levels (e.g., ACE inhibitors, potassium-sparing diuretics)
• Anticoagulants (may enhance effect of warfarin)
• Methotrexate (may increase toxicity)
• Phenytoin (may alter its metabolism)

Precautions

• Monitor renal function regularly, especially in patients with pre-existing renal impairment
• Use with caution in patients with folate deficiency
• May cause photosensitivity
• Assess for signs of hypersensitivity reactions

Pregnancy

Trimethoprim is generally not recommended during pregnancy, especially in the first trimester due to potential teratogenic effects.

Breast-feeding

Trimethoprim is excreted in breast milk, and caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Oral tablets
• Oral suspension

Mechanism of action

Vitamin K is a cofactor of gamma-carboxylase. Gamma carboxylase attaches carboxylic acid functional groups to glutamate, allowing precursors of factors II, VII, IX, and X to bind calcium ions. Binding of calcium ions converts these clotting factors to their active form, which are then secreted from hepatocytes into the blood, restoring normal clotting function. Vitamin K may also carboxylate matrix proteins in chondrocytes, inhibiting calcification of joints, and may increase type II collagen. The role of vitamin K in osteroarthritis, bone density, and vascular calcification is currently under investigation. Vit k is necessary for formation of prothrombinogen & other blood clotting factors in liver. During clotting, circulating prothrombin is required for production of thrombin; in turn, thrombin converts fibrinogen to fibrin, network of which constitutes clot. /vit k/ In normal animals and man, phyltonadione ... /is/ virtually devoid of pharmacodynamic activity. In Animals and man deficient in vitamin k, the pharmacological action of vitamin k is identical to its normal physiological function, that is, to promote hepatic biosynthesis of prothrombin (factor ii), proconvertin (factor vii), plasma thromboplastin component (ptc, christmas factor, factor ix), and Stuart factor (factor x). On the basis of studies of microsomal metabolism in vitro and studies in rats and mice in vivo, /it was suggested/ that vitamin K may be mutagenic by affecting the mixed-function oxidase system which metabolizes benzo(a)pyrene. Phylloquinone at a high concentration (200 umol/l) inhibited the conversion of benzo(a)pyrene to its more polar metabolites, ... . Paradoxically, at a lower concentration of phylloquinone (25 umol/l), ... the metabolism of benzo(a)pyrene was increased. In this system, therefore, .... phylloquinone could either potentiate or inhibit it, depending on the concentration. This overall weaker inhibitory effect of phylloquinone could be due to the low solubility of this lipophilic compound, but it is difficult to explain the mechanism of the enhanced metabolism of benzo(a)pyrene at lower concentrations of phylloquinone.

Pharmacodynamics

Phylloquinone is a vitamin K indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity of vitamin K. It has a long duration of action as vitamin K is cycled in the body, and a wide therapeutic index as large doses can be tolerated. Patients should have their prothrombin time monitored during therapy and healthcare professionals should be aware of the increased risk of hypersensitivity reactions with parenteral administration.

Mechanism of action

Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted. Topical vitamin A can reverse the impairment of wound healing seen in patients receiving corticosteroids, perhaps by restoring the normal inflammatory reaction in the wound. The possibility has been suggested that systemic vitamin A could inhibit the anti-inflammatory effect of systemic corticosteroids. Retinol arrested proliferation of cultured neuroblastoma cells at concentrations of 50 um. A correlation existed between inhibition of growth and inhibition of ornithine decarboxylase in both neuroblastoma cells and glioma cells with retinol. In rats exptl-hypervitaminosis A has been shown ... to produce severe damage of the retina, mainly in the pigment epithelium according to electron microscopy. Alcohol dehydrogenase activity was shown to disappear in the pigment epithelium and visual cells ... . /The authors/ have shown that in an experimental cell culture system consisting of carcinogen-treated 10T1/2 cells, both retinoids and all dietary carotenoids examined can reversibly inhibit neoplastic transformation in the post-initiation phase of carcinogenesis. This activity strongly correlates with their ability to increase gap junctional intercellular communication by up-regulating the expression of the gene CX43 (connexin43). Connexins comprise the structural unit of gap junctions, organelles which allow direct transfer of signals, nutrients and waste products between contacting cells. CX43 is the most widely expressed member of the gap junction family of genes, and we have demonstrated that its expression is strongly down-regulated in human cancers and in several premalignant conditions. When several human tumour cell lines were genetically engineered to conditionally express CX43 under the influence of a tetracycline promoter, their neoplastic phenotype was strongly attenuated. Specifically, induced cells were inhibited from growing in an anchorage-independent manner and, additionally, growth as xenografts in immunocompromised animals was also strongly attenuated. Growth inhibition in suspension was associated both with increased G(1) cell-cycle arrest and with increased apoptosis. /The authors/ propose a model whereby junctional communication allows the transfer of growth inhibitory signals from normal to neoplastic cells and that retinoids and carotenoids, by increasing signal transfer, act to prevent cancer.

Pharmacodynamics

Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.

Mechanism of action

Sulfonamides inhibit the enzymatic conversion of pteridine and p-aminobenzoic acid (PABA) to dihydropteroic acid by competing with PABA for binding to dihydrofolate synthetase, an intermediate of tetrahydrofolic acid (THF) synthesis. THF is required for the synthesis of purines and dTMP and inhibition of its synthesis inhibits bacterial growth. Pyrimethamine and trimethoprim inhibit dihydrofolate reductase, another step in THF synthesis, and therefore act synergistically with the sulfonamides.

Pharmacodynamics

Sulfamethazine is a sulfonamide drug that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for binding to dihydropteroate synthetase (dihydrofolate synthetase). Sulfamethazine is bacteriostatic in nature. Inhibition of dihydrofolic acid synthesis decreases the synthesis of bacterial nucleotides and DNA.

Mechanism of action

Bacteriostatic. Sulfonamides interfere with the biosynthesis of folic acid in bacterial cells; they compete with paraaminobenzoic acid (PABA) for incorporation in the folic acid molecule. By replacing the PABA molecule and preventing the folic acid formation required for DNA synthesis, the sulfonamides prevent multiplication of the bacterial cell. Susceptible organisms must synthesize their own folic acid; mammalian cells use preformed folic acid and, therefore, are not susceptible. Cells that produce excess PABA or environments with PABA, such as necrotic tissues, allow for resistance by competition with the sulfonamide. /Sulfonamides/ Sulfonamides are structural analogs and competitive antagonists of para-aminobenzoic acid (PABA) and thus prevent normal bacterial utilization of PABA for the synthesis of folic acid (pteroylglutamic acid). More specifically, sulfonamides are competitive inhibitors of dihydropteroate synthase,the bacterial enzyme responsible for the incorporation of PABA into dihydropteroic acid, the immediate precursor of folic acid. Sensitive microorganisms are those that must synthesize their own folic acid; bacteria that can utilize preformed folate are not affected. Bacteriostasis induced by sulfonamides is counteracted by PABA competitively. Sulfonamides do not affect mammalian cells by this mechanism, since they require preformed folic acid and cannot synthesize it. /Sulfonamides/